Gyre Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
Gyre Therapeutics, Inc. carries a market capitalization of 764.81M, placing it among publicly traded companies globally. Its enterprise value stands at 4.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 764.81M |
| Enterprise Value | 4.71B |
Share Statistics
Gyre Therapeutics, Inc. currently has 106.03M shares outstanding.
| Shares Outstanding | 106.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Gyre Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 2,860.72. The price-to-sales ratio is 35.06, and the price-to-book ratio stands at 43.99.
| PE Ratio | 2,860.72 |
| PS Ratio | 35.06 |
| PB Ratio | 43.99 |
| P/TBV Ratio | 45.91 |
| P/FCF Ratio | -1,591.93 |
| P/OCF Ratio | -848.23 |
Enterprise Valuation
On an enterprise value basis, Gyre Therapeutics, Inc. trades at an EV/EBITDA multiple of 7,577.92 and an EV/FCF ratio of 2,767.96. The EV/Sales ratio of 39.46 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3,077.90 provides insight into valuation relative to core operating earnings.
| EV / Sales | 39.46 |
| EV / EBITDA | 7,577.92 |
| EV / EBIT | 3,077.90 |
| EV / FCF | 2,767.96 |
Financial Position
Gyre Therapeutics, Inc. maintains a current ratio of 4.26, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.26 |
| Quick Ratio | 3.59 |
| Debt / Equity | 2.40 |
| Debt / EBITDA | -0.33 |
| Interest Coverage | N/A |
Financial Efficiency
Gyre Therapeutics, Inc. posts a return on equity of -18.47 and a return on invested capital of 7.57.
| Return on Equity (ROE) | -18.47 |
| Return on Assets (ROA) | -9.89 |
| Return on Invested Capital (ROIC) | 7.57 |
| Return on Capital Employed (ROCE) | 4.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.67 |
Taxes
Over the trailing twelve months, Gyre Therapeutics, Inc. has paid 3.45M in income taxes, reflecting an effective tax rate of 22.19.
| Income Tax | 3.45M |
| Effective Tax Rate | 22.19 |
Stock Price Statistics
Gyre Therapeutics, Inc.'s stock has declined approximately -9.49868% over the past 52 weeks. The 50-day moving average sits at 6.47, while the 200-day moving average is 7.15.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.49868% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 7.15 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Gyre Therapeutics, Inc. generated 119.38M in revenue and converted that into -17.41M in net income, yielding earnings per share of -0.20. EBITDA reached -10.49M, while operating income came in at -13.62M.
| Revenue | 119.38M |
| Gross Profit | 112.58M |
| Operating Income | -13.62M |
| Pretax Income | -16.11M |
| Net Income | -17.41M |
| EBITDA | -10.49M |
| EBIT | -13.62M |
| Earnings Per Share (EPS) | -0.20 |
Balance Sheet
Gyre Therapeutics, Inc. holds 74.80M in cash and equivalents against 3.42M in total debt, resulting in a net debt position of -43.29M. Total book value stands at 107.93M, with working capital of 93.41M providing operational flexibility.
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 3.42M |
| Net Debt | -43.29M |
| Equity (Book Value) | 107.93M |
| Book Value Per Share | 1.02 |
| Working Capital | 93.41M |
Cash Flow
Gyre Therapeutics, Inc. produced -4.93M in operating cash flow over the past twelve months. After subtracting -2.21M in capital expenditures, free cash flow totaled -7.15M - equivalent to -0.08 per share.
| Operating Cash Flow | -4.93M |
| Capital Expenditures | -2.21M |
| Free Cash Flow | -7.15M |
| FCF Per Share | -0.08 |
Margins
Gyre Therapeutics, Inc. operates with a gross margin of 94.30, reflecting its pricing power and cost economics. The operating margin of -11.41 and net profit margin of -14.58 provide insight into operational efficiency.
| Gross Margin | 94.30 |
| Operating Margin | -11.41 |
| Pretax Margin | -13.49 |
| Profit Margin | -14.58 |
| EBITDA Margin | -8.78 |
Dividends & Yields
The company's payout ratio of 4.65 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 4.65 |
| Shareholder Yield | -0.06 |
| FCF Yield | -0.06 |
Stock Splits
Gyre Therapeutics, Inc.'s most recent stock split took place on October 31, 2023 with a 15:1 split ratio.
| Last Split Date | 10/31/2023 |
| Split Ratio | 15:1 |
Scores
Gyre Therapeutics, Inc. posts an Altman Z-Score of 50.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 50.15 |